Loading clinical trials...
Loading clinical trials...
This study aims to evaluate the electrophysiological properties of the heart conduction system in patients with (increased risk of) ventricular tachyarrhythmias (VTA) and sudden cardiac arrest, and in a control cohort. The electrophysiological properties will be measured with the relatively new technique ECG-Imaging (ECGI). Moreover, clinical data of subjects will be gathered. By combining the data from the data gathering and the results of ECGI, the investigators hope to increase mechanistic understanding of and risk stratification for VTAs. The investigators aim to be able to identify patients at risk of an arrhythmic event, and aim for better treatment strategies in the future.
ECGI combines electrical body-surface mapping with 256 electrodes placed on the thorax with a CT-scan obtaining the anatomy of the heart and torso, hereby able to reconstruct local electrograms, activation and recovery times. In recent research, ECGI provided numerous extra insights into normal cardiac electrophysiology, but also electrophysiological disorders and disease. The results strongly suggest that ECGI can play a pivotal role in further characterizing arrhythmia mechanisms, therefore could do so for VTAs, leading to diagnosis and treatment improvement. Moreover, ECGI seems to have the potential to detect arrhythmogenic substrate in individuals before their first event, offering the possibility to diagnose and treat patients before sudden cardiac arrest occurs. In the BREACH-ECGI study: ECGI will be used to noninvasively characterize the epicardial electrophysiological substrate and triggers of: * Patients with (increased risk of) VTAs * A control cohort. Results will be evaluated for increased mechanistic understanding and risk stratification. Moreover, clinical data of subjects will be gathered. These data will be analyzed to determine their prognostic value in terms of arrhythmia risk
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Jessa Hospital
Hasselt, Limburg, Netherlands
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
Start Date
June 10, 2020
Primary Completion Date
February 12, 2026
Completion Date
February 12, 2026
Last Updated
October 27, 2023
270
ESTIMATED participants
ECG-Imaging
DIAGNOSTIC_TEST
Lead Sponsor
Maastricht University Medical Center
Collaborators
NCT06743789
NCT07263139
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06378996